Valneva SE
0OB3.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$544.29M
Close$
Share Statistics
| Market cap | $544.29 Million |
|---|---|
| Enterprise Value | $633.44 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -195.06% |
|---|---|
| Return on Assets | -40.75% |
| Return on Invested Capital | -41.44% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 4.41 |
| Enterprise Value to EBIT | -5.37 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.33 |
| Debt to Equity | 2.6 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.09
Average shareholder expectationRevenue Estimate
$41.57 M
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.09
Average shareholder expectationRevenue Estimate
$38.20 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Valneva SE
674 employees
CEO: Thomas Lingelbach Founded in Saint-Herblain, France, in 1998, Valneva SE operates as a specialized biotechnology firm, concentrating on the creation and global distribution of preventative vaccines. Its primary focus is on infectious diseases for which cu...